SOX4 and hepatocellular carcinoma: As for miR-129-2, it has been reported to be frequently methylated in hepatocellular carcinoma and gastric cancer [15–17], and methylation-mediated repression of miR-129-2 enhanced oncogenic SOX4 expression in HCC [18], gastric cancer [19], and endometrial cancer [20].